Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership Agreement To Commercialize Vazkepa In Southeast Asia And South Korea
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation (AMRN) has entered into an exclusive partnership agreement with Lotus Pharmaceuticals to commercialize Vazkepa in Southeast Asia and South Korea. The deal is expected to expand Amarin's global footprint and increase its revenue potential.
July 31, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's partnership with Lotus Pharmaceuticals to commercialize Vazkepa in Southeast Asia and South Korea could potentially increase its revenue and expand its global footprint.
The partnership with Lotus Pharmaceuticals allows Amarin to tap into the Southeast Asian and South Korean markets, potentially increasing its revenue and expanding its global presence. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100